Publication Name	World Journal of Hepatology
Manuscript ID	33606
Country	Ireland

Received	2017-02-20 09:51
Peer-Review Started	2017-02-20 18:19
To Make the First Decision	2017-03-28 17:39
Return for Revision	2017-04-01 16:59
Revised	2017-04-20 05:18
Second Decision	2017-06-29 08:35
Accepted by Journal Editor-in-Chief	2017-06-29 10:23
Accepted by Company Editor-in-Chief	2017-07-10 02:46
Articles in Press	2017-07-10 02:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-12 08:35
Publish the Manuscript Online	2017-09-15 05:43

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Authors 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Risk of liver disease in methotrexate treated patients
Manuscript Source	Invited Manuscript
All Author List	Richard Conway and John J Carey
Funding Agency and Grant Number
Corresponding Author	Richard Conway, Centre for Arthritis and Rheumatic Diseases, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland. drrichardconway@gmail.com
Key Words	Liver disease; Transaminases; Fibrosis; Cirrhosis; Methotrexate; Hepatic
Core Tip	Methotrexate is a highly effective treatment for many diseases. In rheumatoid arthritis it controls symptoms, prevents damage, and reduces mortality. The risks of methotrexate use are often over-estimated. Methotrexate may result in asymptomatic transaminase elevations. Historically methotrexate has been in­frequently associated with more severe liver adverse events. With modern monitoring and management of liver blood tests serious liver related adverse events related to methotrexate use appear to be avoidable.
Publish Date	2017-09-15 05:43
Citation	Conway R, Carey JJ. Risk of liver disease in methotrexate treated patients. World J Hepatol 2017; 9(26): 1092-1100
URL	http://www.wjgnet.com/1948-5182/full/v9/i26/1092.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i26.1092

Full Article (PDF)	WJH-9-1092.pdf
Full Article (Word)	WJH-9-1092.doc
Manuscript File	33606-Review.docx
Answering Reviewers	33606-Answering reviewers.pdf
Audio Core Tip	33606-Audio core tip.mp3
Biostatistics Review Certificate	Biostatistics_Statement_20170220045614.docx
Clinical Trial Registration Statement	DeclarationOf_HelsinkiConformation_Statement_20170220045239.docx
Conflict-of-Interest Disclosure Form	33606-Conflict-of-interest statement.pdf
Copyright License Agreement	33606-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20170220045146.docx
Institutional Animal Care and Use Committee Approval Form or Document	Institutional_Animal_Care_and_Use_Committee_Statement_20170220045333.docx
Institutional Review Board Approval Form or Document	Institutional_Review_Board_Statement_20170220045042.docx
Peer-review Report	33606-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33606-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33606-Scientific misconduct check.pdf
Scientific Editor Work List	33606-Scientific editor work list.pdf